Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.

Systemic exposure to obinutuzumab after the Cycle 8 dose ( AUC 21d value) was not dependent on body weight for any of the three lymphoma types (Figure 3 ), although a slight trend for decreased AUC with increased body weight was seen for FL patients ( P = 0.286; P = 0.876 for DLBCL; P = 0.897 for CLL).

also in 4,078 other papers